A 2024 Department of Justice announcement revealed that Medisca Inc., a pharmaceutical ingredient supplier, agreed to pay $21.75 million to resolve False Claims Act allegations. The DOJ alleged that Medisca’s pricing scheme caused pharmacies that purchased its ingredients to submit inflated prescription claims to the Defense Health Agency, allowing them to fraudulently bill federal healthcare programs, often thousands of dollars per prescription.
The case was initiated by a pharmacist who owned and operated a compounding pharmacy and filed a qui tam lawsuit after observing how the inflated ingredient prices worked their way into claims submitted to federal programs.
The Medisca case illustrates something distinctive about compounding pharmacy fraud: the schemes are not always limited to the pharmacy submitting the claim. They can run upstream through the supply chain, downstream through the prescribers, and sideways through the marketers who recruit patients. The False Claims Act applies to all of them.
What Compounding Pharmacies Do and Why They Draw Scrutiny
A compounding pharmacy prepares customized medications for individual patients when commercially available drugs do not meet their specific needs. Compounded drugs may adjust dosage forms, concentrations, or combinations in ways that standard manufactured products cannot. For patients with legitimate needs, compounded medications serve an important function.
Federal health programs, including Medicare, Medicaid, and TRICARE, reimburse compounded prescriptions. The reimbursement rates for specialty compounded drugs are often substantially higher than for standard medications, and that gap between cost and reimbursement has made compounding pharmacies a persistent target for fraud.
Before 2013, TRICARE typically spent approximately $100 million annually on compound drug reimbursements. By 2014, that figure had grown to $1.4 billion, with federal prosecutors estimating that the vast majority of that increase was driven by fraud.
The Primary Fraud Patterns
Compounding pharmacy fraud takes several forms, often running simultaneously within the same scheme.
Kickbacks to Prescribers
A pharmacy or marketer pays physicians, nurse practitioners, or other prescribers to write compounded drug prescriptions for patients, regardless of whether those patients have a genuine clinical need for the medication. The payments can be structured as consulting fees, speaking honoraria, or direct per-prescription payments.
In one settled case, a compounding pharmacy paid kickbacks to outside marketers who, in turn, paid telemedicine doctors to prescribe compounded creams and vitamins without seeing patients, and in some cases without even speaking to them. Every prescription generated through that arrangement produced a tainted claim under the Anti-Kickback Statute, and every tainted claim submitted to a federal program was a false claim.
Inflated Average Wholesale Price
This price manipulation is a different mechanism that targets the ingredient pricing level. AWP is the benchmark used to calculate reimbursements for many compounded prescriptions. When a supplier artificially inflates the AWP for ingredients it sells to pharmacies, those pharmacies submit claims to federal programs based on the inflated benchmark, and the government overpays on every prescription filled. That is precisely what the DOJ alleged in the Medisca case.
Product Substitution Fraud
This occurs when a pharmacy bills for expensive ingredients but compounds using cheaper, non-reimbursable substitutes. In a 2025 settlement, a compounding pharmacy in Georgia agreed to pay $365,000 to resolve allegations that it had billed Medicare, TRICARE, and Medicaid for compounded drugs made with expensive tablets when the drugs were actually made using cheap bulk powders that were not eligible for reimbursement.
Copayment Waivers
These waivers are a related form of inducement. When a pharmacy routinely waives the patient copayment to make compounded drugs effectively free to patients, that waiver is itself a kickback under federal law. It induces the patient’s use of the pharmacy and its products, and every claim submitted in connection with a waiver-based referral is potentially false.
Seeing This Fraud From the Inside
Compounding pharmacy fraud involves many participants, and the people closest to the conduct are often the ones best positioned to report it, including:
- Pharmacists and pharmacy technicians who prepare compound formulations know what ingredients are actually being used and what is being billed.
- Staff who handle prior authorizations and reimbursement paperwork see the discrepancy between what is documented and what was prescribed.
- Sales representatives and marketing staff who recruit patients or physicians for prescription referrals understand the financial arrangements behind those referrals.
- Physicians who receive payment for prescribing compounded drugs at the direction of a marketer, and who may be uneasy about those arrangements, have direct knowledge of the kickback structure.
Any employee or contractor with personal knowledge of these practices may have grounds to file a False Claims Act qui tam lawsuit on behalf of the United States. If the case succeeds, the whistleblower may be eligible to receive a portion of the government’s recovery as compensation for coming forward.
Enforcement Is Ongoing
In fiscal year 2025, the DOJ recovered over $6.8 billion from False Claims Act settlements and judgments, with prescription drug fraud named as one of the key enforcement areas. Compounding pharmacy cases appear consistently in annual DOJ enforcement roundups across healthcare fraud categories, and the range of defendants in recent cases has expanded beyond individual pharmacies to include suppliers, private equity investors, and marketing entities.
The government’s ability to pursue the full chain of a fraud scheme, from ingredient supplier to marketer to prescriber to pharmacy, means that the exposure in compounding fraud cases can be substantial for everyone involved.
Contact a Whistleblower Attorney Before Taking Any Steps
If you work in or around a compounding pharmacy and have witnessed billing for ingredients not used, kickback arrangements between the pharmacy and prescribers or marketers, or claims submitted to Medicare, Medicaid, or TRICARE for prescriptions with no genuine clinical basis, you may have the foundation for a False Claims Act qui tam claim.
Contact Keller Grover today to speak with a whistleblower attorney in confidence. Our team handles False Claims Act cases and can walk you through your rights and options before you take any other steps.